Inotiv Bundle
Who Owns Inotiv?
Understanding Inotiv's ownership is key to its strategy and market standing. A major step was its 2021 rebranding from Bioanalytical Systems, Inc. (BASi) to Inotiv, Inc., unifying its contract research services and reflecting strategic acquisitions.
Founded in 1974 by Purdue University professor Peter Kissinger, Inotiv, Inc. is a leading contract research organization (CRO) headquartered in West Lafayette, Indiana. The company offers extensive nonclinical and analytical drug discovery and development services, alongside research models and products.
As of August 2025, Inotiv's market capitalization stands at approximately $57.7 million, with around 2,075 employees. Its services cover early-stage discovery through preclinical development, including pharmacology, toxicology, and DMPK. The company's public ownership on Nasdaq (NOTV) comprises institutional, insider, and public shareholders, reflecting a diverse investor base. For a deeper look at its market environment, consider the Inotiv PESTEL Analysis.
Who Founded Inotiv?
Inotiv, Inc. began its journey in 1974 as Bioanalytical Systems, Inc. (BASi), founded by Peter Kissinger, a chemistry professor at Purdue University. The company's initial focus was on supplying analytical instruments and consumables to research laboratories, aligning with Kissinger's goal of advancing scientific research.
| Founding Year | 1974 |
| Founder | Peter Kissinger |
| Initial Company Name | Bioanalytical Systems, Inc. (BASi) |
| Initial Focus | Analytical instrumentation and consumables for research laboratories |
Early Vision
Peter Kissinger envisioned supporting scientific discovery by providing advanced tools. This focus on scientific support shaped the company's early trajectory.
Founding Ownership
While specific initial equity details are not widely publicized, the early ownership structure was primarily centered around founder Peter Kissinger.
Initial Operations
The company's inception as BASi laid the foundation for its future in contract research services, particularly in bioanalytical support for drug development.
Early Development
The early period of the company's development was characterized by a focus on its scientific and instrumental offerings, with no significant reported ownership disputes.
Founder's Role
Peter Kissinger, as the founder, was central to the company's initial direction and development. His academic background influenced the company's early focus.
Evolution of Services
From its beginnings in instrumentation, the company gradually evolved its capabilities to provide comprehensive bioanalytical support for the pharmaceutical industry.
The early ownership of the company, then known as BASi, was largely consolidated around its founder, Peter Kissinger. This period saw the company establishing its core competencies in bioanalytical services, crucial for drug development. The absence of widely reported ownership disputes suggests a period of focused growth and development, guided by the founder's vision and expertise. Understanding this foundational period is key to grasping the subsequent evolution of Inotiv ownership. The company's strategic direction, including aspects of its Marketing Strategy of Inotiv, has been influenced by its early emphasis on scientific support and instrumentation.
Key Aspects of Early Inotiv Ownership
The initial ownership structure of the company was primarily driven by its founder, Peter Kissinger. This foundational period established the company's direction in bioanalytical services.
- Founded in 1974 as Bioanalytical Systems, Inc. (BASi).
- Founder: Peter Kissinger, a Purdue University chemistry professor.
- Initial focus on analytical instrumentation and consumables.
- Early ownership centered around the founder, with limited public details on early investors.
- No significant reported ownership disputes during the nascent stage.
Inotiv SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Inotiv’s Ownership Changed Over Time?
The ownership structure of Inotiv, Inc. has seen significant shifts, notably through its public listing in 1997 and a pivotal merger in August 2017. The integration with Seventh Wave Laboratories in 2018 and the subsequent rebranding to Inotiv, Inc. in March 2021 marked key milestones in its corporate evolution.
| Event | Date | Impact on Ownership |
|---|---|---|
| Public Listing (as Bioanalytical Systems, Inc.) | November 25, 1997 | Became a publicly traded entity, opening ownership to public investors. |
| Merger with SPAC | August 2017 | Transitioned to public company status through a merger. |
| Merger with Seventh Wave Laboratories | 2018 | Foundation for the Inotiv brand, consolidating ownership interests. |
| Acquisition of Envigo | November 2021 | Significant expansion, potentially altering ownership percentages due to share issuance or financing. |
| Acquisition of Integrated Laboratory Systems | January 2022 | Further consolidation, financed through cash and debt. |
| Acquisition of Orient BioResource Center | February 2022 | Continued expansion, impacting the company's financial and ownership landscape. |
| Acquisition of Protypia | July 2022 | Further integration and potential shifts in ownership. |
Inotiv's ownership landscape is characterized by a substantial presence of institutional investors and significant insider holdings, reflecting a blend of broad market participation and concentrated control by key individuals. These holdings have seen fluctuations, with institutional ownership reported at approximately 26.84% in April 2025 and later at 25.43% by August 2025, indicating active trading and portfolio adjustments by large investment entities.
Key Stakeholders in Inotiv's Ownership
Understanding who owns Inotiv is crucial for assessing its corporate governance and strategic direction. Major shareholders and insiders play a significant role in the company's trajectory.
- Institutional investors collectively held about 26.84% of shares as of April 2025.
- Mutual funds represented approximately 12.94% of ownership in April 2025.
- Balyasny Asset Management L.P. was a top institutional holder with 1,654,648 shares as of June 30, 2025.
- Vanguard Group Inc. held 1,383,848 shares as of June 30, 2025.
- Insider ownership was around 30.47% in April 2025, decreasing to 9.15% by August 2025.
- Robert W. Leasure, Jr., President and CEO, held 12.81% of shares as of March 13, 2025.
- Dr. John E. Sagartz, Director and Chief Strategy Officer, owned 6.82% of shares as of March 13, 2025.
Inotiv PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Inotiv’s Board?
The current Board of Directors at Inotiv, Inc. is instrumental in guiding the company's strategic direction and overseeing its operations. This board comprises both executive and independent members, ensuring a balance of internal expertise and external oversight. The executive leadership team includes key figures responsible for the company's day-to-day management and strategic planning.
| Board Member | Role |
|---|---|
| R. Matthew Neff | Non-Executive Chairman of the Board |
| Robert W. Leasure, Jr. | President and Chief Executive Officer; Director |
| Dr. John E. Sagartz | Director and Chief Strategy Officer |
| Terry Coelho | Independent Director |
| Michael J. Harrington | Independent Director |
| David Landman | Independent Director |
| Dr. Nigel Brown | Independent Director |
| Beth A. Taylor | Senior Vice President, Finance and Chief Financial Officer |
Inotiv operates under a straightforward voting structure where each common share holds one vote, adhering to a one-share-one-vote principle. As of January 14, 2025, the company had 33,717,962 common shares outstanding. There are no other classes of voting securities, and shareholders do not possess cumulative voting rights. This means that voting power is directly tied to the number of shares owned, making significant shareholders influential in corporate decisions. Understanding this structure is key to grasping Target Market of Inotiv and who controls the company.
Inotiv's Voting Power Dynamics
Inotiv's voting power is concentrated in its common shares, with each share granting one vote. This system ensures that ownership directly translates to influence in corporate governance.
- 33,717,962 common shares outstanding as of January 14, 2025.
- One-share-one-vote principle applied.
- No cumulative voting rights for shareholders.
- Voting power directly proportional to share ownership.
Inotiv Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Inotiv’s Ownership Landscape?
Inotiv, Inc. has experienced significant shifts in its ownership structure over the past few years, largely influenced by strategic financial maneuvers and key acquisitions. These events have reshaped the company's profile and its shareholder base.
| Event | Date | Impact on Ownership/Liquidity |
|---|---|---|
| Public Offering of Common Shares | December 2024 | Raised $25.5 million at $4.25 per share for working capital and capital expenditures. |
| Subsequent Issuance of Common Shares | Q1 Fiscal Year 2025 | Enhanced liquidity by $27.5 million. |
| Acquisition of Envigo | November 2021 | Expanded research models and services, implicitly altering ownership through share issuances or debt. |
| Acquisition of Integrated Laboratory Systems | January 2022 | Acquired for $56 million, impacting asset base and ownership structure. |
| Acquisition of Orient BioResource Center | February 2022 | Acquired for $51 million, further reshaping the company's asset base. |
| Acquisition of Protypia | July 2022 | Acquisition completed, contributing to the evolving corporate structure. |
Institutional investors maintain a consistent presence in the company's ownership landscape. As of August 2025, institutional holdings represented 25.43% of the company's shares, with significant entities like Balyasny Asset Management L.P. and Vanguard Group Inc. being notable stakeholders. Insider holdings, while experiencing minor fluctuations, remained substantial at approximately 30.47% as of April 2025, indicating continued confidence from company leadership. A cybersecurity incident reported on August 8, 2025, which affected certain systems and data, could indirectly influence investor sentiment and, consequently, ownership dynamics, although no direct impacts on ownership structure from this event have been publicly detailed. There have been no prominent reports of planned privatizations or major leadership changes that would fundamentally alter the broader ownership trends beyond standard succession planning.
Institutional Investor Activity
Institutional ownership stood at 25.43% in August 2025. Key investors include Balyasny Asset Management L.P. and Vanguard Group Inc.
Insider Holdings
Insider ownership was around 30.47% in April 2025. This indicates significant stakeholding by company executives and directors.
Strategic Acquisitions' Impact
Acquisitions like Envigo, Integrated Laboratory Systems, Orient BioResource Center, and Protypia have expanded the company's operations and asset base.
Recent Capital Infusion
A public offering in December 2024 raised $25.5 million, with further share issuances in early 2025 adding $27.5 million to liquidity.
Inotiv Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Inotiv Company?
- What is Competitive Landscape of Inotiv Company?
- What is Growth Strategy and Future Prospects of Inotiv Company?
- How Does Inotiv Company Work?
- What is Sales and Marketing Strategy of Inotiv Company?
- What are Mission Vision & Core Values of Inotiv Company?
- What is Customer Demographics and Target Market of Inotiv Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.